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Introduction
The development of tumour-specific, fluorescent smart
probes has the potential to improve the early diagnosis of
cancer and metastatic spread. TKTL1 thereby seems an
interesting enzyme to target, as it has been described to be
overexpressed in a number of malignancies. It plays a cen-
tral role in the pentose phosphate pathway, and its over-
expression might lead to a selection advantage in tumour
cells as their metabolism might become widely independ-
ent of the presence of oxygen. Therefore, they can survive
under the common hypoxic conditions within tumours,
while at the same time lactate and CO2 production
increase, which in turn promotes matrix degradation and
favours metastasis formation.
Methods
The aim of this preliminary project is the analysis of
TKTL1 expression in upper aerodigestive tract epithelial
cells of different sites. Prior to this it seemed mandatory to
verify the specificity of the commercially available TKTL1
antibody. Therefore, we analysed stable transfectants of
HEK 293 cells via immunoblot and siRNA transfection.
Furthermore, TKTL1 mRNA levels in carcinoma cell lines
were determined via RT-PCR.
Results
The main protein band of TKTL1 at 65 kD was detected,
however along with two additional protein bands, which
occurred in control cells, too. Downregulation of TKTL1
via specific siRNA showed an effect on the main protein
band, while the additional protein bands remained unaf-
fected. These results suggest an unspecific binding of the
antibody in addition to the specific TKTL1 detection.
Conclusion
Some future experiments with stable transfectants and
siRNA should show if TKTL1 expression mediates a prolif-
eration advantage in head and neck carcinomas.
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